OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/27/21
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for IndustryGlobeNewsWire • 06/24/21
Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise CarePRNewsWire • 06/02/21
OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Optinose Reports First Quarter 2021 Financial Results and Operational UpdatesGlobeNewsWire • 05/05/21
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference PresentationGlobeNewsWire • 04/28/21
New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every DayPRNewsWire • 04/27/21
OptiNose's (OPTN) CEO Peter Miller on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/03/21
OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/24/21
OptiNose's Business Is Thriving While OptiNose Trades At Lower Revenue Multiples Than PeersSeeking Alpha • 12/01/20
OptiNose, Inc. (OPTN) CEO Peter Miller on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/07/20
Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 MillionGlobeNewsWire • 10/22/20
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid SpraysPRNewsWire • 09/29/20